Molecular and genetic basis of sudden cardiac death

Alfred L. George Jr.

Departments of Medicine and Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.

The abrupt cessation of effective cardiac function due to an aberrant heart rhythm can cause sudden and unexpected death at any age, a syndrome called sudden cardiac death (SCD). Annually, more than 300,000 cases of SCD occur in the United States alone, making this a major public health concern. Our current understanding of the mechanisms responsible for SCD has emerged from decades of basic science investigation into the normal electrophysiology of the heart, the molecular physiology of cardiac ion channels, fundamental cellular and tissue events associated with cardiac arrhythmias, and the molecular genetics of monogenic disorders of heart rhythm. This knowledge has helped shape the current diagnosis and treatment of inherited arrhythmia susceptibility syndromes associated with SCD and has provided a pathophysiological framework for understanding more complex conditions predisposing to this tragic event. This Review presents an overview of the molecular basis of SCD, with a focus on monogenic arrhythmia syndromes.

Introduction

When a person dies suddenly and unexpectedly from a suspected cardiovascular cause, the term sudden cardiac death (SCD) is used to classify the mortal event. SCD is frequently caused by an abrupt change in heart rhythm (arrhythmia), most often ventricular tachycardia (VT) or ventricular fibrillation (VF), that impairs cardiac pumping, thereby depriving vital organs of oxygenated blood. A brief episode of VT or VF may cause only momentary loss of consciousness (syncope), but death is the inevitable result of sustained VF in the absence of emergent medical care. Estimates of the annual SCD incidence vary but are generally in the range of 50–100 per 100,000 persons in industrialized nations (1). In the United States, previous estimates have been as high as 450,000 deaths per year (2), representing a large fraction of total mortality due to heart disease and a substantial public health burden. These statistics largely reflect adult deaths in the setting of ischemic heart disease or heart failure, but children can also be susceptible to SCD in the context of certain genetic disorders.

Understanding the root causes of SCD has been an important research endeavor for several decades, and much progress has been made in defining the cellular, molecular, and genetic basis for ventricular arrhythmogenesis, the main pathophysiological provocateur of SCD (3). Mendelian (i.e., monogenic) syndromes predisposing to life-threatening ventricular arrhythmias in young adults and children are genetically heterogeneous, with more than 25 genes identified so far (Table 1). Molecular mechanisms related to these conditions involve membrane ion channels important for cardiomyocyte electrogenesis or regulation of intracellular Ca²⁺ homeostasis. By contrast, the genetic risk for SCD in older adults is more complex, with few if any unifying hypotheses about molecular mechanisms, although some overlap is observed with susceptibility to monogenic arrhythmia. Furthermore, the respective contributions of genetic and acquired factors to pathogenesis vary along the spectrum of age, with inborn errors having the greatest impact on SCD risk in younger subjects and acquired factors dominating risk in older subjects.

This Review presents an overview of the molecular basis of SCD, with a focus on monogenic arrhythmia syndromes. The emerging picture of SCD risk as a complex genetic trait in older subjects has been reviewed elsewhere (4, 5). An initial brief summary of basic arrhythmia mechanisms at the cellular and tissue levels will provide a framework for presenting the molecular underpinnings.

Ventricular arrhythmia mechanisms

The normal initiation and orderly propagation of the cardiac impulse through the heart requires a tightly orchestrated sequence of changes in ionic currents that sum to produce the dynamic and phasic change in membrane potential referred to as the cardiac action potential (Figure 1). Abnormal properties of ionic currents can cause electrical disorder and lead to aberrant impulse generation or propagation. Consequently, rapid and sometimes chaotic electrical activity in the ventricles ensues, manifesting as either VT or VF that can lead to SCD. In a simplistic model, there are two major prerequisites for arrhythmic events: a vulnerable myocardial substrate and a trigger.

Myocardial conditions that increase risk for arrhythmias include structural (anatomical) and functional causes of heterogeneous conduction velocity that disrupt the normal orderly propagation of action potential waves through the ventricles (6). Heterogeneous conduction can predispose to the emergence of spiral waves, impulses that travel in a circular pattern around an anatomic barrier, as in ischemic or scarred myocardium, or around a point of reentry known as a rotor in non-ischemic and structurally normal myocardium (7). If uninterrupted, rhythmic spiral wave propagation in the ventricles will be associated with VT, but degeneration or fragmentation into smaller wavelets creates the more chaotic impulse movement associated with VF. Transmural dispersion of repolarization can also predispose to reentry. Normally, there is heterogeneity of action potential duration across the wall of the ventricles, with shorter action potentials occurring in the epicardial layer. This phenomenon arises from a more prominent epicardial transient outward current (Iₒ). Exaggeration of this transmural heterogeneity can create circumstances in which the fully repolarized epicardium can be reexcited by depolarized mid-myocardial and endocardial layers (8, 9).

Conflict of interest: The author has declared that no conflict of interest exists.

Citation for this article: J Clin Invest. 2013;123(1):75–83. doi:10.1172/JCI62928.
### Table 1

**Genes involved in monogenic causes of SCD**

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Genea</th>
<th>Protein</th>
<th>Effect of mutation</th>
<th>OMIM identifiera</th>
</tr>
</thead>
<tbody>
<tr>
<td>LQTS</td>
<td>KCNQ1 (11p15.5)</td>
<td>K⁺ voltage-gated channel, KQT-like subfamily, member 1 (Kᵥ7.1)</td>
<td>Loss of function, reduced Iᵥ</td>
<td>607542</td>
</tr>
<tr>
<td></td>
<td>KCNQ2 (7q35)</td>
<td>K⁺ voltage-gated channel, subfamily H (eag-related), member 2 (Kᵥ11.1; HERG)</td>
<td>Loss of function, reduced Iᵥ</td>
<td>152427</td>
</tr>
<tr>
<td></td>
<td>SCN5A (3p21)</td>
<td>Na⁺ channel, voltage-gated, type V, α subunit (Naᵥ1.5)</td>
<td>Impaired inactivation, increased persistent Iₙa</td>
<td>600163</td>
</tr>
<tr>
<td></td>
<td>ANK2 (4q25)</td>
<td>Ankyrin 2, neuronal</td>
<td>Aberrant localization of ion transporters</td>
<td>106410</td>
</tr>
<tr>
<td></td>
<td>KCNE1 (21q22.1)</td>
<td>K⁺ voltage-gated channel auxiliary subunit</td>
<td>Reduced Iₛ</td>
<td>176261</td>
</tr>
<tr>
<td></td>
<td>KCNE2 (21q22.1)</td>
<td>K⁺ voltage-gated channel auxiliary subunit</td>
<td>Reduced Iₛ</td>
<td>603796</td>
</tr>
<tr>
<td></td>
<td>CAV3 (3p25)</td>
<td>Caveolin 3</td>
<td>Increased persistent Iₙa</td>
<td>601253</td>
</tr>
<tr>
<td></td>
<td>SCN4B (11q23)</td>
<td>Na⁺ channel, voltage-gated, type IV, β subunit</td>
<td>Increased persistent Iₙa</td>
<td>608256</td>
</tr>
<tr>
<td></td>
<td>SNTA1 (20q11.2)</td>
<td>Syntrophin, α1</td>
<td>Increased persistent Iₙa</td>
<td>601017</td>
</tr>
<tr>
<td></td>
<td>AKAP9 (7q21)</td>
<td>A kinase (PRKA) anchor protein (yotiao) 9</td>
<td>Reduced Iₛ</td>
<td>604001</td>
</tr>
<tr>
<td></td>
<td>KCNJ5 (11q24)</td>
<td>K⁺ inwardly rectifying channel, subfamily J, member S (Kir3.4)</td>
<td>Reduced Iₛ,ATP</td>
<td>600734</td>
</tr>
</tbody>
</table>

Jervell and Lange-Nielsen syndrome

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Genea</th>
<th>Protein</th>
<th>Effect of mutation</th>
<th>OMIM identifiera</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>KCNQ1 (11p15.5)</td>
<td>K⁺ voltage-gated channel, KQT-like subfamily, member 1 (Kᵥ7.1)</td>
<td>Loss of function, reduced Iᵥ</td>
<td>607542</td>
</tr>
<tr>
<td></td>
<td>KCNE1 (21q22.1)</td>
<td>K⁺ voltage-gated channel auxiliary subunit</td>
<td>Reduced Iₛ</td>
<td>176261</td>
</tr>
</tbody>
</table>

Andersen syndrome

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Genea</th>
<th>Protein</th>
<th>Effect of mutation</th>
<th>OMIM identifiera</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>KCNJ2 (17q23.1)</td>
<td>K⁺ inwardly rectifying channel, subfamily J, member 2 (Kir2.1)</td>
<td>Loss of function, reduced Iₖ</td>
<td>600861</td>
</tr>
</tbody>
</table>

Timothy syndrome

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Genea</th>
<th>Protein</th>
<th>Effect of mutation</th>
<th>OMIM identifiera</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CACNA1C (12p13.3)</td>
<td>Ca²⁺ channel, voltage-dependent, L type, α1C subunit (Caᵥ1.2)</td>
<td>Gain of function, increased Iₙa</td>
<td>114205</td>
</tr>
</tbody>
</table>

SQTS

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Genea</th>
<th>Protein</th>
<th>Effect of mutation</th>
<th>OMIM identifiera</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>KCNQ1 (11p15.5)</td>
<td>K⁺ voltage-gated channel, KQT-like subfamily, member 1 (Kᵥ7.1)</td>
<td>Gain of function, increased Iᵥ</td>
<td>607542</td>
</tr>
<tr>
<td></td>
<td>KCNH2 (7q35)</td>
<td>K⁺ voltage-gated channel, subfamily H (eag-related), member 2 (Kᵥ11.1; HERG)</td>
<td>Gain of function, increased Iᵥ</td>
<td>152427</td>
</tr>
<tr>
<td></td>
<td>KCNJ2 (17q23.1)</td>
<td>K⁺ inwardly rectifying channel, subfamily J, member 2 (Kir2.1)</td>
<td>Gain of function, increased Iₖ</td>
<td>600861</td>
</tr>
<tr>
<td></td>
<td>CACNA1C (12p13.3)</td>
<td>voltage-gated Ca²⁺ channel, Caᵥ1.2</td>
<td>Loss of function, reduced Iₙa</td>
<td>114205</td>
</tr>
<tr>
<td></td>
<td>CACNB2 (10p12)</td>
<td>Ca²⁺ channel, voltage-dependent, β2 subunit</td>
<td>Loss of function, reduced Iₙa</td>
<td>600003</td>
</tr>
<tr>
<td></td>
<td>CACNA2D1 (7q21)</td>
<td>Ca²⁺ channel, voltage-dependent, α2δ subunit 1</td>
<td>Loss of function, reduced Iₙa</td>
<td>114204</td>
</tr>
</tbody>
</table>

BrS

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Genea</th>
<th>Protein</th>
<th>Effect of mutation</th>
<th>OMIM identifiera</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SCN5A (3p21)</td>
<td>Na⁺ channel, voltage-gated, type V, α subunit (Naᵥ1.5)</td>
<td>Loss of function, reduced Iₙa</td>
<td>600163</td>
</tr>
<tr>
<td></td>
<td>GPD1L (3q22.3)</td>
<td>glycerol-3-phosphate dehydrogenase 1-like</td>
<td>Reduced Iₙa</td>
<td>611778</td>
</tr>
<tr>
<td></td>
<td>SCN1B (19q13.1)</td>
<td>Na⁺ channel, voltage-gated, type I, β subunit</td>
<td>Reduced Iₙa</td>
<td>600235</td>
</tr>
<tr>
<td></td>
<td>SCN3B (11q23.3)</td>
<td>Na⁺ channel, voltage-gated, type III, β subunit</td>
<td>Reduced Iₙa</td>
<td>608214</td>
</tr>
<tr>
<td></td>
<td>MOG1 (17p13.1)</td>
<td>RAM guanine nucleotide release factor</td>
<td>Reduced Iₙa</td>
<td>607954</td>
</tr>
<tr>
<td></td>
<td>KCND3 (1p13.3)</td>
<td>K⁺ voltage-gated channel, Shal-related subfamily, member 3 (Kir4.3)</td>
<td>Gain of function, increased Iₙa</td>
<td>605411</td>
</tr>
<tr>
<td></td>
<td>KCNE1 (11q13)</td>
<td>K⁺ voltage-gated channel auxiliary subunit</td>
<td>Increased Iₖ</td>
<td>604433</td>
</tr>
<tr>
<td></td>
<td>KCNE5 (Xq22.3)</td>
<td>K⁺ voltage-gated channel auxiliary subunit</td>
<td>Increased Iₖ</td>
<td>300328</td>
</tr>
<tr>
<td></td>
<td>CACNA1C (12p13.3)</td>
<td>Ca²⁺ channel, voltage-dependent, L type, α1C subunit (Caᵥ1.2)</td>
<td>Loss of function, reduced Iₙa</td>
<td>114205</td>
</tr>
<tr>
<td></td>
<td>CACNB2 (10p12)</td>
<td>Ca²⁺ channel, voltage-dependent, β2 subunit</td>
<td>Loss of function, reduced Iₙa</td>
<td>600003</td>
</tr>
<tr>
<td></td>
<td>KCNJ6 (12p12.1)</td>
<td>K⁺ inwardly rectifying channel, subfamily J, member 8 (Kir6.1)</td>
<td>Gain of function, increased Iₙa,ATP</td>
<td>600935</td>
</tr>
</tbody>
</table>

CPVT

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Genea</th>
<th>Protein</th>
<th>Effect of mutation</th>
<th>OMIM identifiera</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RYR2 (1q42.1)</td>
<td>Ryanodine receptor 2 cardiac</td>
<td>Gain of function, increased SR Ca²⁺ release</td>
<td>180902</td>
</tr>
<tr>
<td></td>
<td>CASQ2 (1p13.3)</td>
<td>Calsequestrin 2 cardiac muscle</td>
<td>Loss of function, reduced Iₙa</td>
<td>114251</td>
</tr>
<tr>
<td></td>
<td>TRDN (6q22)</td>
<td>Triadin</td>
<td>Impaired regulation of SR Ca²⁺ release</td>
<td>603283</td>
</tr>
</tbody>
</table>

---

*a Chromosomal location given in parentheses. bOnline Mendelian Inheritance in Man (http://www.ncbi.nlm.nih.gov/omim).*
A focal ectopic impulse generated in the ventricles can trigger the initiation of spiral waves and cause reentrant arrhythmias. At the cellular level, early afterdepolarizations (EADs) or delayed afterdepolarizations (DADs) provide the most common mechanisms for ectopic excitation. EADs arise during the plateau phase of the cardiac action potential, whereas DADs emerge after completion of an action potential (Figure 2 and refs. 10, 11). Both events occur because of aberrant depolarizing ionic currents. In the case of EADs, increased activation of voltage-gated (L-type) Ca$^{2+}$ channels or persistent activation of voltage-gated Na$^+$ channels are the usual mechanisms. By contrast, DADs arise from spontaneous intracellular Ca$^{2+}$ release and efflux of Ca$^{2+}$ through the electrogenic Na$^+$/Ca$^{2+}$ exchanger (NCX; stoichiometry 3Na$^+$:1Ca$^{2+}$), evoking a transient inward Na$^+$ current (INa) and a small amount of residual Ito, and emerging outward currents carried by K$^+$ channels. Activation of two types of K$^+$ currents (IKr, IK1) in concert with inactivation of Ca$^{2+}$ channels tips the balance in favor of the outward current, thereby promoting phase 3 repolarization. Finally, the inward rectifying K$^+$ current (IK1) finishes the job of repolarizing myocyte membranes. Other electrogenic transporters (NCX, Na$^+$/K$^+$ ATPase) are involved in maintaining intracellular ion homeostasis in the face of large ion fluxes accompanying each action potential.

Many ion channels involved with the generation and propagation of cardiac action potentials are regulated by several factors, most notably β-adrenergic stimulation. In particular, during exercise or stress in which the sympathetic nervous system is activated (fight or flight response), heart rate acceleration requires shortening of the action potential duration, and this is accomplished in part by activating Ito through a CAMP-dependent mechanism. Sympathetic stimulation also enhances contractility of the heart, mainly through augmentation of Ca$^{2+}$ influx (activation of ICa) and increased loading of the SR so that more Ca$^{2+}$ can be released intracellularly during systole.

**Cardiac action potential**

The generation and propagation of action potentials in heart muscle as well as excitation-contraction coupling are physiological events dependent upon a symphony of ion channels acting in concert with many associated regulatory or interacting proteins. Ion channels are ubiquitous proteins that confer selective ionic permeability to cell membranes. Voltage-gated ion channels are opened and closed by changes in membrane potential, whereas ligand-gated ion channels require binding of intracellular or extracellular molecules to open an ionic pore. Voltage-gated ion channels with selective permeability for Na$^+$, K$^+$, and Ca$^{2+}$ ions feature prominently in normal cardiac electrophysiology and in the molecular pathogenesis of monogenic disorders predisposing to SCD (Table 1).

**Monogenic causes of SCD**

Two categories of monogenic heart disease predispose to SCD. These are genetic disorders of heart rhythm and familial cardiomyopathy. Cardiomyopathy is discussed in depth elsewhere in this Review series (13), and therefore the focus here will be on genetic arrhythmia susceptibility. Although rare, these syndromes have been tractable at the molecular level, and nearly two decades of research have uncovered molecular mechanisms that may be shared with more common acquired conditions. The genes responsible for congenital arrhythmia syndromes for the most part encode either ion channel subunits or proteins that interact with ion channels (Table 1).

**Figure 1**

ECG and the cardiac action potential. Approximate temporal relationships between surface ECG (A) and typical ventricular action potential (B). Individual ionic currents responsible for different phases of the action potential are labeled and represented schematically in (B). In the ECG (A), the P wave indicates atrial depolarization, whereas the QRS complex indicates ventricular depolarization. The T wave indicates ventricular repolarization, and the Q-T interval indicates the time for the entire ventricular depolarization and repolarization sequence to occur. The ionic events underlying a cardiac action potential are illustrated in (C) and include the depolarizing inward Na$^+$ (INa) and calcium (ICa) currents, and the repolarizing transient outward current (Ito), and three outward potassium currents (IKr, IKs, IK1).
idiopathic VF, and catecholaminergic polymorphic VT (CPVT). Three general mechanisms responsible for arrhythmia susceptibility have been elucidated in these disorders: abnormal repolarization (LQTS, SQTS, BrS), slow ventricular conduction (BrS), and aberrant intracellular Ca\(^{2+}\) homeostasis (CPVT).

**Congenital LQTS.** The QT interval measured by standard surface ECG provides a surrogate measurement of the average ventricular action potential duration. Both a prolonged or shortened QT interval indicates an increased risk of life-threatening cardiac arrhythmia (14, 15). Congenital LQTS is characterized clinically by an increased risk of potentially fatal ventricular arrhythmias, especially torsades de pointes (16), manifesting as syncope, cardiac arrest, and SCD in otherwise healthy young adults and children. The syndrome is most often transmitted in families as an autosomal dominant trait (Romano-Ward syndrome) and less commonly as an autosomal recessive disease combined with deafness (Jervell and Lange-Nielsen syndrome). Autosomal dominant LQTS occurs in approximately 1 in 2,500 live births (17).

LQTS is genetically heterogeneous and can be caused by mutations in several genes encoding voltage-gated K\(^{+}\) channel subunits (\(KCNQ1, KCNH2, KCNE1, KCNE2\)) (18–23), voltage-gated Na\(^{+}\) channel subunits (\(SCN5A, SCN4B\)) (24, 25), an L-type Ca\(^{2+}\) channel (\(CACNA1C\)) (26), inwardly rectifying K\(^{+}\) channel (\(I_{Kr}\)) (encoding the A-kinase anchor protein also known as yotiao) exert similar functional effects on \(I_{Kr}\) but are much less common (31, 33). Similarly, \(KCNE2\) mutations associated with LQTS may disrupt HERG function and reduce \(I_{Kr}\) but sometimes only during pharmacological suppression of this current (22, 34).

In autosomal-dominant LQTS, mutations in \(KCNQ1\) and \(KCNH2\) may exert dominant-negative effects on the respective wild-type allele. Dominant-negative effects are best explained by the formation of dysfunctional tetrameric channel complexes with mixtures of wild-type and mutant subunits. Recessive \(KCNQ1\) and \(KCNE1\) mutations are responsible for Jervell and Lange-Nielsen syndrome (21, 23, 35) but do not exhibit dominant-negative effects, most likely because mutant proteins are not stable or do not form heteromultimers with wild-type subunits.

Impaired trafficking of mutant subunits is a common in vitro observation for \(KCNH2\) mutations (36, 37). For some \(KCNH2\) mutations, impaired trafficking can be corrected pharmacologically in heterologous cells (38), thus stimulating interest in this approach for therapy of LQT2. Modeling the effects of human \(KCNQ1\) and \(KCNH2\) mutations in vivo (e.g., genetically modified mice) have been challenging because of substantial differences in repolarizing currents in mouse heart. However, recent prog-
Acquired LQTS is more common than congenital LQTS but shares similar pathophysiological mechanisms. Drug-induced LQTS (diLQTS), the most common form of acquired LQTS, occurs when cardiac or non-cardiac drugs block HERG channels, suppress $I_{Na}$, and cause delayed repolarization (49). A genetic predisposition to diLQTS has been hypothesized, and this notion has received support from genetic association studies (50, 51). A common KCNE1 variant (DS85N) carried by 1%–2% of the general population is overrepresented among diLQTS cases (52). The variant confers a partial loss-of-function upon $I_{Na}$ and causes a condition referred to as reduced repolarization reserve that predisposes to overt LQTS upon collateral inhibition of $I_{Na}$ (53). Anecdotal evidence also suggests that latent congenital LQTS may be unmasked by HERG-blocking drugs (54, 55) or other physiological provocations such as acute myocardial infarction (56).

Syndromic LQTS: Andersen and Timothy syndromes. In addition to Jervell and Lange-Nielsen syndrome, two other LQTS subtypes have prominent extracardiac manifestations. Andersen syndrome is an autosomal dominant disorder characterized by ventricular arrhythmias, periodic paralysis, and dysmorphic facial and skeletal features (27, 57). Considerable phenotypic variability exists among people diagnosed with Andersen syndrome, with many subjects exhibiting only one or two clinical features (58, 59). Although ventricular arrhythmia can be a prominent feature, this only rarely precipitates SCD (60).

Andersen syndrome is associated with mutations in KCNJ2 encoding the Kir2.1 inward rectifier K+ channel (27, 61, 62) that is responsible for the main component of $I_{Kr}$, an important current driving phase 3 repolarization (63). Dominant-negative, loss-of-function KCNJ2 mutations reduce $I_{Kr}$ and cause prolongation of the action potential duration, with increased propensity for re-entrant arrhythmias (62, 64, 65). Some identified KCNJ2 mutations are predicted to affect residues important for the regulation of Kir2.1 channel activity by phosphatidylinositol 4,5-bisphosphate (66). Other alleles impair trafficking of the channel to the plasma membrane (67, 68). Previous investigation of mice with homozygous deletion of $Kcnj2$ demonstrated premature death secondary to cleft palate but no overt ventricular arrhythmias despite lack of measurable $I_{Kr}$ in cardiac myocytes (64, 69). By contrast, in vitro suppression of $I_{Kr}$ in isolated canine left ventricle caused delayed action potential repolarization, increased transmural dispersion of repolarization, and polymorphic VT resembling cardiac features of Andersen syndrome (70, 71).
In Timothy syndrome, mutations in CACNA1C, which encodes the voltage-gated Ca\(^{2+}\) channel pore-forming subunit (Ca\(_v\)1.2), cause a complex phenotype including cardiac arrhythmia, syndactyly, and autism spectrum disorder (26). The syndrome exhibits sporadic occurrence as opposed to Mendelian inheritance, but a candidate gene survey demonstrated a common heterozygous mutation (G406R) in CACNA1C consistent with de novo mutagenesis or parental mosaicism (26). A second mutation (G402S) was subsequently discovered (72). Both mutations occur within one of two mutually exclusive exons (exons 8 or 8A) present in alternatively spliced CACNA1C transcripts. Functionally, both mutations cause substantial impairment of channel inactivation, predicting an increased Ca\(^{2+}\) current during the plateau phase of the action potential (26, 72). Selective impairment of voltage-dependent inactivation rather than Ca\(^{2+}\)-dependent inactivation may be the main functional disturbance (73). This gain-of-function defect leads to increased Ca\(^{2+}\) entry and activation of calmodulin-dependent kinase II, stimulating a proarrhythmic cascade in isolated rabbit ventricular myocytes (74). Mice with heterozygous or homozygous expression of a Timothy syndrome mutation are not viable.

SQTS. Another disorder of repolarization, the SQTS, was described more recently and appears to be much rarer than LQTS (75). As in LQTS, subjects with SQTS can be stricken with life-threatening ventricular arrhythmias and SCD, often during childhood. Mutations in six different genes encoding either K\(^{+}\) channel (KCNJ1, KCNH2, KCNJ2) (76–78) or Ca\(^{2+}\) channel (CACNA1C, CACNB2, CACNA2D1) (79, 80) subunits have been associated with this phenotype. Many of these SQTS genes are the same as those implicated in LQTS, but the functional consequence of mutations is opposite. Mutations in K\(^{+}\) channels encoded by KCNH2 and KCNJ1 that cause SQTS exhibit gain-of-function effects predicted to enhance repolarizing power and shorten action potential duration (76, 77), effects that are modeled in zebrafish carrying mutant zERG channels with altered gating properties (81). By contrast, mutations in genes encoding Ca\(^{2+}\) channel subunits exhibit loss of function (79, 80). Mutations in KCNJ2 also confer a gain of function that for some alleles stems from unique biophysical behaviors, such as loss of inward rectification (82).

BrS. Individuals with BrS have an increased risk for potentially lethal ventricular arrhythmias usually occurring during sleep, but in the absence of myocardial ischemia, electrolyte abnormalities or structural heart disease (83). Individuals with the disease may exhibit a characteristic baseline ECG pattern consisting of ST elevation in the right precordial leads, apparent right bundle branch block, but normal QT intervals. Administration of Na\(^{+}\) channel blocking agents (e.g., procainamide, flecainide, ajmaline) (84) and fever (85) may unmask this ECG pattern in latent cases. A family history of unexplained sudden death is typical. The sudden unexplained death syndrome is clinically similar to BrS and causes sudden death, typically during sleep, in young and middle-aged males, with a higher prevalence in individuals from Southeast Asian countries (86–88). Inheritance is autosomal dominant with incomplete and often low penetrance and a substantial male predominance. One attractive hypothesis to explain incomplete penetrance in BrS is the existence of genetic modifiers that may be common variants in SCN5A or other genes (89–91).

Mutations in SCN5A account for less than 30% of BrS cases with known genotypes. Reduced I\(_{Na}\) is the primary pathophysiological mechanism due to loss-of-function mutations including frameshifts, splice site defects, or premature stop codons (92, 93) that are predicted to encode nonfunctional Na\(^{+}\) channels. Also, some missense mutations have been demonstrated to be nonfunctional either because of impaired protein trafficking to the cell membrane or presumed disruption of ion conductance (94–96). Other missense mutations are dysfunctional, with biophysical defects predicted to reduce channel availability such as altered voltage dependence of activation, more rapid fast inactivation, and enhanced slow inactivation (97–99). Reduced I\(_{Na}\) may also be the consequence of mutations in other genes that less frequently cause BrS, including those encoding Na\(^{+}\) channel β subunits (SCN1B, SCN3B) (100, 101) or glycerol-3-phosphate dehydrogenase 1-like.
of epicardial action potentials because of (114). Heterozygous knockout mice (Scn5a+/–)(112, 113) and the mechanism has gained support primarily from clinical observations right ventricular outflow tract (RVOT) (108–111). This mechanism is supported by elegant work using the canine ventricular wedge model (8, 9). The second hypothesis postulates that the main effect of reduced myocardial Isat is slowing of impulse conduction in the right ventricle and delayed activation of the right ventricular outflow tract (RVOT) (108–111). This mechanism has gained support primarily from clinical observations including electroanatomic mapping studies (112, 113) and the observed therapeutic benefit of epicardial ablation over the RVOT (114). Heterozygous Scn5a knockout mice (Scn5a+/–) have provided an animal model of BrS (115–117). Whether these two hypotheses are mutually exclusive or whether all cases of BrS originate by the same pathophysiological mechanism remains unclear.

CPVT. Alternations in intracellular Ca2+ homeostasis can also promote life-threatening ventricular arrhythmias and precipitate SCD. In the monogenic disorder CPVT, abnormal control or regulation of Ca2+ release from the SR can trigger DADs and cause ventricular arrhythmias (118). The condition is usually diagnosed during childhood and typically presents with syncope or SCD in the setting of exercise, emotional stress, or other circumstances associated with a surge in catecholamine release (119).

Mutations in RyR2 encoding the cardiac ryanodine receptor/ Ca2+ release channel are associated with autosomal dominant CPVT (120). Autosomal recessive forms of the disorder are associated with mutations in either CASQ2, encoding the SR Ca2+-binding protein casquestrin (121), or TRDN, encoding triadin, which links RyR2 with casquestrin (122). These three proteins reside together within the terminal cisterna of the SR, where intracellular membranes lie adjacent to the transverse tubule (T tubule) region of the plasma membrane. Normally, electrical impulses conducted into the T tubules activate voltage-gated L-type Ca2+ channels and evoke a wave of Ca2+ influx sufficient to promote Ca2+-induced Ca2+ release through RYR2. Release of Ca2+ from the SR promotes myocyte contraction (excitation-contraction coupling), which is then terminated by removal of cytosolic Ca2+ mostly by reuptake into the SR by a Ca2+-ATPase pump (SERCA) and through exchange for extracellular Na+ by an electrogenic NCX on the plasma membrane (Figure 4). Spontaneous SR Ca2+ release during diastole can be evoked by β-adrenergic stimulation by several proposed mechanisms (123, 124).

CPVT-associated RyR2 mutations sensitizes the channel to luminal Ca2+, leading to exaggerated spontaneous SR Ca2+ release (125). The effects of CASQ mutations are more complex and include a loss of SR Ca2+ buffering, loss of RyR2 regulation by casquestrin, and remodeling of SR ultrastructure (126–128). Loss of triadin, as in some cases of recessive CPVT (122), may also predispose to unregulated SR Ca2+ release by disrupting normal regulation of intracellular Ca2+ homeostasis. In Trdn knockout mice, attenuated Ca2+-dependent inactivation of L-type Ca2+ channels appears to promote SR Ca2+ overload and the predisposition to aberrant SR Ca2+ release (129).

Summary and future directions

Fundamental molecular and genetic mechanisms of SCD have been elucidated by investigations of rare monogenic disorders of heart rhythm. Despite the identification of more than 25 causal genes, there remain many subjects with inherited arrhythmia susceptibility who do not have mutations, which suggests that other, unidentified genes exist. Newer strategies such as exome and whole genome sequencing may be valuable to uncover additional molecular etiologies. Efforts to understand mechanisms responsible for incomplete penetrance, including identification of modifier genes, will also contribute to deciphering the complex relationships between genotype and phenotype. Finally, better disease models such as cardiomyocytes derived from human-induced pluripotent stem cells created from patients with monogenic disorders predisposing to SCD, as described elsewhere in this Review series (130), may also help advance our understanding of SCD pathophysiology and inspire new therapeutic approaches.

Acknowledgments

The author is supported by grants from the NIH (HL083374 and HL068880).

Address correspondence to: Alfred L. George Jr., Division of Genetic Medicine, 529 Light Hall, Vanderbilt University, 2215 Garland Avenue, Nashville, Tennessee 37232-0275, USA. Phone: 615.936.2660; Fax: 615.936.2661; E-mail: al.george@vanderbilt.edu.


review series